Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
1LFirst line
5-FUFluorouracil (5-fluorouracil)
ADCCAntibody-dependent cellular cytotoxicity
AEAdverse event
AHFSAmerican Hospital Formulary Service
aPTTActivated partial thromboplastin time
ASCOAmerican Society of Clinical Oncology
ASTAspartate aminotransferase
AUCArea under the curve
AUC0–168hArea under the plasma concentration versus time curve from 0 to 168 hours
BIABudget impact analysis
BICRBlinded independent central review
BLABiologics License Application
BRAFB-Raf proto-oncogene
BTDBreakthrough Therapy Designation
CBRClinical benefit rate
CD4Cluster of differentiation 4
CD8Cluster of differentiation 8
CDKN2ACyclin-dependent kinase inhibitor 2A
CEACost-effectiveness analysis
CFCisplatin and fluorouracil
CHOChinese hamster ovary
CHUMCentre hospitalier de l'Université de Montréal
CIConfidence interval
CLClearance
CLIAClinical Laboratory Improvement Amendments
CmaxMaximal concentration
cORRConfirmed objective response rate
COSTComprehensive Score for Financial Toxicity
CPCisplatin and paclitaxel
CPSCombined positive score
CRComplete response
CrClCreatinine clearance
CXCL10C-X-C motif chemokine ligand 10
CXCL9C-X-C motif chemokine ligand 9
D1Day 1
DCRDisease control rate
DDSDose determination set
DFSDisease-free survival
DLTDose-limiting toxicity
DNADeoxyribonucleic acid
DORDuration of response
EBVEpstein-Barr virus
ECOGEastern Cooperative Oncology Group
EEEfficacy evaluable
EESEfficacy-evaluable set
EGFEpidermal growth factor
EGFREpidermal growth factor receptor
EMTEpithelial-mesenchymal transition
EORTCEuropean Organisation for Research and Treatment of Cancer
EQ-5D-3LEuroQol 5-dimension 3-level instrument
ERBB2Erb-b2 receptor tyrosine kinase 2
ESMOEuropean Society for Medical Oncology
EUEuropean Union
EU5France, Germany, Italy, Spain, and the United Kingdom
EXTREMECetuximab plus platinum and fluorouracil
FASFull analysis set
FAT1FAT atypical cadherin 1
FDAFood and Drug Administration
FDQFinancial Distress Questionnaire
FGFR1Fibroblast growth factor receptor 1
FICERAFicerafusp alfa
FTFinancial toxicity
FUFluorouracil
G4SGlycine-glycine-glycine-glycine-serine peptide linker unit
GHSGlobal health status
GLOBOCANGlobal Cancer Incidence, Mortality and Prevalence
HBVHepatitis B virus
HCRUHealth care resource utilization
HCVHepatitis C virus
hEGFRHuman epidermal growth factor receptor
HEKHuman embryonic kidney
HER2Human epidermal growth factor receptor 2
HFXHyperfractionated radiation therapy
HIVHuman immunodeficiency virus
HNHead and neck
HNCHead and neck cancer
HNSCCHead and neck squamous cell carcinoma
HPVHuman papillomavirus
HPV16Human papillomavirus type 16
HRHazard ratio
HR-HPVHigh-risk human papillomavirus
HRQoLHealth-related quality of life
HSCTHematopoietic stem cell transplantation
HSUVHealth state utility value
ICERIncremental cost-effectiveness ratio
ICFInformed consent form
ICIImmune checkpoint inhibitor
IDMCIndependent data monitoring committee
IFN-γInterferon gamma
IgG1Immunoglobulin G1
IHCImmunohistochemistry
IL-10Interleukin 10
IMRTIntensity-modulated radiotherapy
INHBIncremental net health benefit
INMBIncremental net monetary benefit
INNInternational Nonproprietary Name
IOImmuno-oncology
IQRInterquartile range
iRECISTResponse Evaluation Criteria in Solid Tumors for immune-based therapeutics
IRRInfusion-related reaction
ISHIn situ hybridization
iTregInducible regulatory T cell
ITTIntention-to-treat
IVIntravenous
LALocally advanced
LCLocal control
mAbMonoclonal antibody
MDTMultidisciplinary team
mHNCMetastatic head and neck cancer
moMonth
mOSMedian overall survival
mPFSMedian progression-free survival
MSDMerck Sharp & Dohme
MTDMaximum tolerated dose
MTXMethotrexate
N/ANot applicable
NANot applicable
NCCNNational Comprehensive Cancer Network
NCINational Cancer Institute
NENot estimable
NJNew Jersey
NMNot mature
NOTCH1Notch receptor 1
NRNot reached
NSNot significant
NSCLCNon-small cell lung cancer
NSD1Nuclear receptor binding SET domain protein 1
OBDOptimal biological dose
OOPOut-of-pocket
OPCOropharyngeal cancer
OPSCCOropharyngeal squamous cell carcinoma
OROdds ratio
ORRObjective response rate
OSOverall survival
PCRPolymerase chain reaction
PDProgressed disease
PD-1Programmed cell death protein 1
PD-L1Programmed death-ligand 1
PD-L2Programmed death-ligand 2
pembroPembrolizumab
PFSProgression-free survival
PFS2Progression-free survival 2
PKPharmacokinetics
POOral administration
PPPMPer patient per month
PPTPost-platinum therapy
PRPartial response
PSPerformance status
pSMAD2Phosphorylated SMAD family member 2
PTProthrombin time
ptsPatients
Q2WEvery 2 weeks
Q3WEvery 3 weeks
Q6WEvery 6 weeks
QALYQuality-adjusted life-year
QLQ-C30Quality of Life Questionnaire Core 30
QLQ-H&N35Quality of Life Questionnaire head and neck cancer-specific module, 35 questions
QoLQuality of life
QWOnce weekly
R/MRecurrent or metastatic
RASRAS family of proto-oncogenes
RDRecommended dose
RECISTResponse Evaluation Criteria in Solid Tumors
rHNCRecurrent head and neck cancer
RNARibonucleic acid
RTRadiotherapy
RTOGRadiation Therapy Oncology Group
rwOSReal-world overall survival
rwToTReal-world time on treatment
rwTTNTReal-world time to next treatment
SASafety analysis
SAESerious adverse event
SBRTStereotactic body radiotherapy
SCACSquamous cell carcinoma of the anal canal
SCAISalvage chemotherapy after immunotherapy
SCCSquamous cell carcinoma
SCCACSquamous cell carcinoma of the anal canal
SCCHNSquamous cell carcinoma of the head and neck
SCTSalvage chemotherapy
SDStable disease; standard deviation
SEERSurveillance, Epidemiology, and End Results
SMAD4SMAD family member 4
SPTSecond primary tumor
TEAETreatment-emergent adverse event
TGF-betaTransforming growth factor beta
TGF-βTransforming growth factor beta
TGFβRIITransforming growth factor beta receptor II
TMETumor microenvironment
TNBCTriple-negative breast cancer
TNF-αTumor necrosis factor alpha
TP53Tumor protein p53
TPExDocetaxel, cisplatin, and cetuximab
TPSTumor proportion score
TRAETreatment-related adverse event
TSGTumor suppressor gene
TTTime toxicity
TTDTime to deterioration
TTRTime to response
Tyr1068Tyrosine residue 1068
UCUniversity of California
ULNUpper limit of normal
UPMCUniversity of Pittsburgh Medical Center
USUnited States
USAUnited States of America
USCUniversity of Southern California
VEGFVascular endothelial growth factor
vsVersus
WACWholesale acquisition cost
WHOWorld Health Organization
WOCBPWomen of childbearing potential
WSWait and see
WTPWillingness-to-pay